71/100BCorpay stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Corpay is 468.67, 1.4% above the current price of 462.22. Their targets range from 406.00 to 536.00.
Of the 11 firms that rated Corpay in the past 12 months, 8 rate it buy or strong buy, 3 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 406.00 to 536.00, with an average of 468.67.
| Buy | 8 | |
| Hold | 3 | |
| Sell | 0 |
12-month price target
| Highest target | 536.00 |
| Average target | 468.67 |
| Lowest target | 406.00 |
| Current price | 462.22 |
Corpay price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Corpay price target and rating?
How analysts rate Corpay, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
8 of 11 firms rate it buy now, against 5 of 9 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Corpay analyst upgrades, downgrades and price targets
The latest rating change came on 26 January 2026, when Morgan Stanley upgraded Corpay from Equal Weight to Overweight. Its price target is 379.00, from 356.00. The most recent new target came from RBC Capital on 5 November 2026: 474.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 5 Nov 2026 | RBC Capital Daniel Perlin | Reiterated · Sector Perform | 438.00 → 474.00 | +8.2% | 454.41 |
| 28 Oct 2026 | Morgan Stanley | Reiterated · Overweight | 455.00 → 460.00 | +1.1% | 395.20 |
| 2 Sept 2026 | Scotiabank | — | 536.00 | — | 404.81 |
| 31 Aug 2026 | RBC Capital | Reiterated · Sector Perform | 423.00 → 438.00 | +3.5% | 407.88 |
| 25 Aug 2026 | Wolfe Research | Reiterated · Outperform | 475.00 → 530.00 | +11.6% | 413.92 |
| 10 Aug 2026 | Cantor Fitzgerald Ramsey El-Assal | Reiterated · Overweight | 385.00 → 480.00 | +24.7% | 397.20 |
| 7 Aug 2026 | Morgan Stanley | — | 415.00 → 455.00 | +9.6% | 397.55 |
| 6 Aug 2026 | Robert W. Baird David Koning | — | 475.00 | — | 394.15 |
| 6 Aug 2026 | UBS | Reiterated · Neutral | 380.00 → 415.00 | +9.2% | 390.51 |
| 6 Aug 2026 | RBC Capital | Reiterated · Sector Perform | 363.00 → 423.00 | +16.5% | 394.53 |
| 6 Aug 2026 | Wolfe Research Darrin Peller | — | 450.00 → 475.00 | +5.6% | 394.53 |
| 6 Aug 2026 | Raymond James Madison Suhr | — | 361.00 → 442.00 | +22.4% | 394.53 |
| 28 Jul 2026 | Morgan Stanley Michael Infante | Reiterated · Overweight | 400.00 → 415.00 | +3.8% | 379.71 |
| 3 Jun 2026 | Wolfe Research | — | 450.00 | — | 359.82 |
| 18 May 2026 | Loop Capital Markets | — | 406.00 | — | 348.50 |
| 10 May 2026 | Morgan Stanley | — | 390.00 → 400.00 | +2.6% | 343.99 |
| 8 May 2026 | Oppenheimer | — | 378.00 → 388.00 | +2.6% | 338.65 |
| 5 Mar 2026 | Raymond James John Davis | — | 392.00 → 361.00 | -7.9% | 324.33 |
| 10 Feb 2026 | UBS | Reiterated · Neutral | 380.00 | — | 354.96 |
| 6 Feb 2026 | Mizuho Securities Dan Dolev | Reiterated · Neutral | 340.00 | — | 335.00 |
| 5 Feb 2026 | RBC Capital | Reiterated · Sector Perform | 363.00 | — | 331.01 |
| 5 Feb 2026 | Oppenheimer | — | 380.00 → 378.00 | -0.5% | 331.13 |
| 5 Feb 2026 | Morgan Stanley Michael Infante | Reiterated · Overweight | 379.00 → 390.00 | +2.9% | 300.28 |
| 26 Jan 2026 | Cantor Fitzgerald Ramsey El-Assal | — | 385.00 | — | 324.00 |
| 26 Jan 2026 | Morgan Stanley | Upgraded · Equal Weight → Overweight | 356.00 → 379.00 | +6.5% | 320.52 |
| 5 Dec 2025 | Oppenheimer Rayna Kumar | Upgraded · Perform → Outperform | 380.00 | — | 297.39 |
Corpay EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Corpay's EPS to grow 35.6% a year until 2028, faster than over the last 5 years (13.1% a year) and the last 3 years (6.6%).
Analysts expect Corpay's revenue to grow 12.1% a year until 2028, about as fast as over the last 5 years (13.6% a year) and the last 3 years (9.7%).
Revenue
EPS
Does Corpay beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 1.9% off the result, either way, and their revenue estimate 1.4%, over the last 12 quarters.
- EPS beats
- 16 / 19
- Revenue beats
- 14 / 19
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +1.7%
- Since
- May 2022
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 4 Nov 2026 | 7.20 | 7.54 | +4.7% | 1.36B | 1.38B | +1.7% |
| Q2 FY2026 | 5 Aug 2026 | 6.58 | 7.00 | +6.4% | 1.30B | 1.34B | +3.0% |
| Q1 FY2026 | 7 May 2026 | 5.47 | 5.80 | +6.0% | 1.21B | 1.26B | +4.0% |
| Q4 FY2025 | 4 Feb 2026 | 5.95 | 6.04 | +1.5% | 1.23B | 1.25B | +1.1% |
| Q3 FY2025 | 5 Nov 2025 | 5.63 | 5.70 | +1.2% | 1.16B | 1.17B | +0.8% |
| Q2 FY2025 | 6 Aug 2025 | 5.12 | 5.13 | +0.2% | 1.10B | 1.10B | +0.2% |
| Q1 FY2025 | 6 May 2025 | 4.51 | 4.51 | 0.0% | 1.02B | 1.01B | -1.0% |
| Q4 FY2024 | 5 Feb 2025 | 5.37 | 5.36 | -0.2% | 1.05B | 1.03B | -1.6% |
| Q3 FY2024 | 7 Nov 2024 | 4.97 | 5.00 | +0.6% | 1.03B | 1.03B | +0.3% |
| Q2 FY2024 | 7 Aug 2024 | 4.51 | 4.55 | +0.9% | 975.48M | 975.71M | +0.0% |
| Q1 FY2024 | 8 May 2024 | 4.09 | 4.10 | +0.2% | 938.15M | 935.25M | -0.3% |
| Q4 FY2023 | 7 Feb 2024 | 4.48 | 4.44 | -0.9% | 967.01M | 937.30M | -3.1% |
Corpay stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Corpay's earnings grow at the 20.6% a year analysts expect to FY2028, then 15.0% a year, it would earn about 49.58 a share in FY2030. At the P/E it has traded at over the last five years (14.6 to 25.1) that is 721.58 to 1,243.39 a share, or 1,041.31 at its average P/E of 21.0. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 28.00 | 407.46 | 588.01 | 702.12 |
| FY2027 | 31.99 | 465.60 | 671.90 | 802.29 |
| FY2028 | 37.49 | 545.62 | 787.38 | 940.18 |
| FY2029 (extrapolated) | 43.11 | 627.46 | 905.49 | 1,081.21 |
| FY2030 (extrapolated) | 49.58 | 721.58 | 1,041.31 | 1,243.39 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (14.6, 21.0, 25.1).
Is Corpay stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Corpay's P/E of 25.1 is near the top of its 5-year range (13.3 to 27.2, median 20.9). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 0.7 on expected growth against 1.6 on its median P/E and past five years' growth. Growing 35.6% a year, Corpay earns a P/E of 25.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 31.48, a fair value of 786.88; the price, 462.22, is 41.3% below it. Its forward P/E, on the consensus for FY2026, is 16.5.
Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 18.8 and 31.3). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 25.08
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 20.92
- Five-year P/E range
- 13.3 – 27.2
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 16.51
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.22
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +1.4%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.